Previous Article | Next Article 
Journal of Clinical Microbiology, May 2000, p. 1977-1980, Vol. 38, No. 5
Center of Liver Diseases and Department of
Surgery, University of Hong Kong Medical Center, Queen Mary
Hospital, Pokfulam, Hong Kong
Received 8 November 1999/Returned for modification 19 January
2000/Accepted 21 February 2000
This study evaluated the applicability of quantitative PCR (Q-PCR)
and branched-chain DNA assays for detection of hepatitis B virus (HBV)
DNA in sera. For 42 samples, the detection rates were 81 and 41%,
respectively, with a correlation coefficient of 0.633. The Q-PCR is
useful for early monitoring of HBV load in high-risk patients.
Hepatitis B virus (HBV) is an
important etiologic agent of liver diseases. Reinfection of HBV in
liver transplant patients often results in a poor prognosis
(1), and reactivation of HBV is also seen with
hepatocellular carcinoma (HCC) after surgical intervention
(4). Laboratory surveillance on HBV activity in those
high-risk patients is urgently needed. Viral load assay has been
considered the most effective method for evaluating the effectiveness
of anti-HBV drugs, as well as for monitoring the efficacy of
prophylactic measures (10, 16, 17). The prevailing HBV DNA
assays include probe hybridization-based and PCR-based viral DNA target
detection. However, studies evaluating the performance of these assays
in clinical settings are scanty, especially those involving patients
with low serum HBV levels. The present study compared the efficacy of
quantitative PCR (Q-PCR) (AcuGen HBV quantitative test; Biotronic
Corp., Lowell, Mass.) (15, 23) with the branch-chained DNA
(b-DNA) assay (Quantiplex HBV DNA; Chiron Corp., Emeryville,
Calif.) (7, 8, 20-22) for detection of HBV in patients with
liver diseases.
Forty-two serum samples from 17 patients (14 HCC and 3 liver
transplant) admitted to the surgical ward of Queen Mary Hospital (Pokfulam, Hong Kong) were collected perioperatively using different time schedules and were stored in aliquots at PCR was performed using 1 µl of a viral DNA template extracted from
200 µl of sera, 2.5 pmol of primers (5'-TTACAGGCGGGGTTTTTCTT-3' and 5'-AAGATGTTGTACAGACTTGG-3', which amplify a 585-bp
fragment of the HBV surface antigen [S] gene), a 62.5 µM
concentration of each deoxynucleoside triphosphate, 2 µM
MgCl2, and 1.25 U of Taq DNA polymerase (GIBCO).
The PCR was carried out in a thermal cycler (MJ Research Inc., Waltham,
Mass.) in 40 cycles of 94°C for 30 s, 55°C for 30 s, and
72°C for 1 min. The amplification products were analyzed by 2%
agarose gel electrophoresis and ethidium bromide staining.
The Quantiplex HBV DNA assay was employed according to the
manufacturer's instructions. Briefly, samples were added to
microplates precoated with two different sets of oligonucleotides
derived from the conserved regions of the HBV genome: the 3' regions of surface and core antigen genes. Viral DNA was captured by
oligonucleotides used to coat the plate. After incubation with the HBV
DNA target probes, the b-DNA amplifier hybridized to the target probes
and was further amplified by an alkaline phosphatase-dioxetane
substrate reaction. The chemiluminescent signal was read using a
luminometer, and each reading represented the mean ± the standard
deviation from duplicate determinations.
The AmpliSensor HBV assay (AcuGen) consists of two amplification steps:
(i) an initial asymmetric amplification to overproduce one strand of
the target sequence and (ii) a subsequent heminested amplification to
monitor AmpliSensor (a fluorogenic primer duplex) as it is converted
into the amplification product. The asymmetric primer set (sense,
5'-TGCTCGTGTTACAGGCGCCGT-3'; antisense,
5'-GAGGCATAGCAGCAGGATGAAGAG-3') was designed to
asymmetrically amplify a 241-bp HBV S DNA fragment (14). AmpliSensor primer
5'-TTATCGCTGGATGTGTCTGCGGCGT-3' (sense) was used to
further amplify and detect a 64-bp fragment from within the asymmetric
amplification products. The profiles for amplification and detection
were as follows: (i) 95°C for 25 s, 60°C for 25 s, and
72°C for 40 s and (ii) 95°C for 20 s, 60°C for 20 s, and 2°C for 30 s, respectively.
Data were analyzed by SPSS statistical software (SPSS Inc., Chicago,
Ill.). The Mann-Whitney or Wilcoxon rank test was used to compare
continuous variables, while chi-square test or Fisher's exact test was
used for discrete variables. Pearson correlation was to analyze data
from two quantitative assays. Assay reproducibility was assessed by
coefficient of variation. A two-tailed hypothesis was tested in all
cases, and a P value of <0.05 was considered significant.
All patients selected were positive for one or more HBV serological
markers (Table 1). In general, the HBV
DNA titer obtained from the b-DNA assay correlated well with that from
the AmpliSensor Q-PCR (correlation coefficient = 0.633, P < 0.001). The reproducibilities of both the
AmpliSensor and b-DNA assays were good, with coefficients of variation
of 6.4 and 6.5%, respectively. Table 2
summarizes the results of the conventional PCR, AmpliSensor Q-PCR, and
b-DNA assays. The AmpliSensor Q-PCR was shown to be highly sensitive compared to the b-DNA assay and conventional PCR. Samples with low HBV
titers (0.002 to 0.7 Meq/ml, i.e., below the cutoff of the b-DNA assay)
were detectable by the AmpliSensor Q-PCR. By contrast, the performance
of the b-DNA test was particularly good for samples with high titers of
HBV DNA. Furthermore, the conventional PCR was found to be useful for
confirmation of results for samples with titers of 1.23 Meq/ml or
higher. Seventy-nine percent and 67% of the results from the b-DNA and
AmpliSensor tests, respectively, were validated by PCR. Thus, a
combination of the AmpliSensor or b-DNA test with PCR can enhance the
accuracy of HBV detection. Each b-DNA assay, which costs $80 per test,
takes about 24 h in order to report a definitive result, whereas
the AcuGen Q-PCR costs around $5 per test and is completed in about 8 to 10 h.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Evaluation of Quantitative PCR and Branched-Chain
DNA Assay for Detection of Hepatitis B Virus DNA in Sera from
Hepatocellular Carcinoma and Liver Transplant Patients
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
80°C until analysis. Four HBV serological markers (HBsAg, HBeAg, HBeAb, and HBcAb) were
evaluated in each sample, using a monoclonal quantitative enzyme
immunoassay (Auszyme; Abbott) and the IMX HBe 2, anti-HBe 2, and core
assay kits (Abbott), respectively. The tests were performed by
following the manufacturer's procedures for the microparticle enzyme
immunoassay for qualitative determination of HBeAg, HBeAb, and HBcAb in
human serum or plasma.
TABLE 1.
Analysis of HBV DNA by conventional PCR, AuGen Q-PCR, and
Chiron b-DNA assays in serum samples from
HBV-seropositive patientsa
TABLE 2.
Qualitative relation among AmpliSensor Q-PCR, b-DNA
assay, and conventional PCR results
The Quantiplex b-DNA assay is the most frequently used method for HBV DNA detection (7, 8, 20-22), with reported high accuracy and good reproducibility. However, its low sensitivity compared with that of the PCR assay is a major limitation. A handful of quantitative PCR methods, such as the Amplicor and AmpliSensor assays, were recently developed to enhance the sensitivity for viral DNA (6, 18, 24). The Amplicor assay for quantification of hepatitis C virus RNA was recently evaluated (5), and it also demonstrated better sensitivity than the Digene hybridization assay for HBV DNA detection in samples from patients with chronic HBV (9). Furthermore, the AmpliSensor HBV quantitative test, a format similar to the Amplicor assay, has also been applied with good success for screening HBV DNA in blood intended for transfusion (3).
HBV viral load has become a useful index for predicting disease progress and for evaluating the efficacy of antiviral treatment of patients with chronic HBV infection (10, 11, 16, 17, 19). For transplant patients, reinfection with HBV or emergence of virus mutants definitely influences the prognosis of graft survival. Thus, a slight change in viral load may have important clinical implications (13). HBV replication often happens at low titers in most HBV-infected HCC patients (2, 12), and unfortunately, surgical treatment for HCC and/or postoperative adjuvant chemotherapy may result in reactivation of viral activity, further destroying the liver parenchyma and inducing cirrhosis. Therefore, early surveillance of the changes in the viral load may yield a better prognosis for these patients.
Although the b-DNA assay provides accurate results, it may not be suitable for patients with low HBV titers. The AmpliSensor Q-PCR appears to provide a relatively cheap, fast, and sensitive approach, particularly useful in HBV surveillance schemes for early prediction of slight changes in viral DNA level in transplant patients. Because of the small number of samples used in this study, a broader prospective evaluation is being undertaken to validate the present data; the evaluation includes patients with pre- or postantiviral therapy, serial specimens from uncomplicated patients, and other patients whose sera contain a wide range of HBV DNA levels.
| |
ACKNOWLEDGMENTS |
|---|
This work is supported by the Development Fund for Area of Excellence (University of Hong Kong) and the Hong Kong Research Grants Council (HKU7281/98M) to J.M.L.
We gratefully acknowledged Ms. Maggie Ho for preparing the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, 1 Jimmy Fund Way, SM-624, Boston, MA 02115. Phone: (617) 525-1251. Fax: (617) 525-1310. E-mail: jmluk{at}hkucc.hku.hk.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Angus, P. W. 1997. Review: hepatitis B and liver transplantation. J. Gastroenterol. Hepatol. 12:217-223[Medline]. |
| 2. | Beasley, R. P. 1988. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956[CrossRef][Medline]. |
| 3. | Cardoso, M. S., K. Koerner, and B. Kubanek. 1998. Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results. Transfusion 38:905-907[CrossRef][Medline]. |
| 4. | Chen, T., Q. J. Ou, J. S. Chen, Q. L. Deng, and F. C. Zhang. 1998. Hepatitis B virus replication status and its response to surgery for tumor in hepatocellular carcinoma with positive markers of HBV. Chin. J. Surgery 36:652-654. (In Chinese.) |
| 5. | Francoise, L., C. Pascale, V. Damien, P. Christopher, D. Bruno, F. Lionel, R. Dorothee, B. Christine, P. Jean-Charles, and H. Jean-Marie. 1999. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assays. Hepatology 29:528-535[CrossRef][Medline]. |
| 6. | Hagiwara, H., N. Hayashi, E. Mita, T. Takehara, A. Kasahara, H. Fusamoto, and T. Kamada. 1993. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104:877-883[Medline]. |
| 7. | Hendricks, D. A., B. J. Stowe, B. S. Hoo, J. Kolberg, B. D. Irvine, P. D. Neuwald, M. S. Urdea, and R. P. Perrillo. 1995. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am. J. Clin. Pathol. 104:537-546[Medline]. |
| 8. | Hess, G., and M. Reuschling. 1993. Toward routine diagnosis of hepatitis B virus desoxyribonucleic acid. Clin. Biochem. 26:289-293[CrossRef][Medline]. |
| 9. | Kessler, H. H., K. Pierer, E. Dragon, H. Lackner, B. Santner, D. Stunzner, E. Stelzl, B. Waitzl, and E. Marth. 1998. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin. Diagn. Virol. 9:37-43[CrossRef][Medline]. |
| 10. | Lok, A. S. F. 1994. Treatment of chronic hepatitis B. J. Viral Hepatol. 1:105-124[Medline]. |
| 11. | Lok, A. S. F., O. C. K. Ma, and J. Y. N. Lau. 1991. Interferon alpha therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. Gastroenterology 100:756-761[Medline]. |
| 12. | Lok, A. S. F., and O. C. K. Ma. 1990. Hepatitis B virus replication in Chinese patients with hepatocellular carcinoma. Hepatology 12:582-588[Medline]. |
| 13. | Niesters, H. G., P. Honkoop, E. B. Haagsma, R. A. de Man, S. W. Schalm, and A. D. Osterhaus. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177:1382-1385[Medline]. |
| 14. |
Okamoto, H.,
M. Imai,
M. Shimozaki,
Y. Hoshi,
H. Iizuka,
T. Gotanda,
F. Tsuda,
Y. Miyakawa, and M. Mayumi.
1986.
Nucleotide sequence of a cloned hepatitis B virus genome, subtype ayr: comparison with genomes of the other three subtypes.
J. Gen. Virol.
67:2305-2314 |
| 15. |
Ozaki, H., and L. W. McLaughlin.
1992.
The estimation of distances between specific backbone-labeled sites in DNA using fluorescence resonance energy transfer.
Nucleic Acids Res.
20:5205-5214 |
| 16. | Pastore, G., T. Santantonio, M. Milella, L. Monno, N. Mariano, R. Moschetta, and L. Pollice. 1992. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J. Hepatol. 14:221-225[CrossRef][Medline]. |
| 17. | Perrillo, R. P., E. R. Schiff, G. L. Davis, H. C. Bodenheimer, Jr., K. Lindsay, J. Payne, J. L. Dienstag, C. O'Brien, C. Tamburro, I. M. Jacobson, R. Sampliner, D. Feit, J. Lefkowitch, M. Kuhns, C. Meschievitz, B. Sanghvi, J. Albrecht, A. Gibas, and the Hepatitis International Therapy Group. 1990. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 323:295-301[Abstract]. |
| 18. | Ranki, M., H. M. Schatzl, R. Zachoval, M. Uusi-Oukari, and P. Lehtovaara. 1995. Quantification of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection. Hepatology 21:1492-1499[CrossRef][Medline]. |
| 19. | Schmilovitz-Weiss, H., M. Levy, N. Thompson, and G. Dusheiko. 1993. Viral markers in the treatment of hepatitis B and C. Gut 34:S26-S35. |
| 20. | Urdea, M. S., T. Horn, T. I. Fultz, M. Anderson, J. A. Running, S. Hamren, D. Ahle, and C. A. Chang. 1991. Branched amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp. Ser. 24:197-200. |
| 21. | Urdea, M. S., I. Kolberg, B. D. Warner, and T. Horn. 1990. A novel method for the rapid detection of hepatitis B virus in human serum samples without blotting or radioactivity, p. 275-292. In K. VanDyke, and R. VanDyke (ed.), Luminescence immunoassay and molecular applications. CRC Press Inc., Boca Raton, Fla. |
| 22. | Urdea, M. S., B. D. Warner, J. A. Running, M. Stempien, J. Clyne, and T. Horn. 1988. A comparison of non-radioisotopic hybridization assay methods using fluorescent, chemiluminescent and enzyme labeled synthetic oligodeoxyribonucleotide probes. Nucleic Acids Res. 16:937-956. |
| 23. | Wang, C. N., K. Y. Wu, and H. T. Wang. 1995. Quantitative PCR using the Amplisensor assay, p. 193-202. In C. W. Dieffenbach, and G. S. Dveksler (ed.), PCR primer: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 24. | Yun, Z., J. Lundeberg, B. Johansson, A. Hedrum, O. Weiland, M. Uhlen, and A. Sonnerborg. 1994. Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. J. Virol. Methods 47:1-13[CrossRef][Medline]. |
Journal of Clinical Microbiology, May 2000, p. 1977-1980, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Laperche, S., Thibault, V., Bouchardeau, F., Alain, S., Castelain, S., Gassin, M., Gueudin, M., Halfon, P., Larrat, S., Lunel, F., Martinot-Peignoux, M., Mercier, B., Pawlotsky, J.-M., Pozzetto, B., Roque-Afonso, A.-M., Roudot-Thoraval, F., Saune, K., Lefrere, J.-J.
(2006). Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.. J. Clin. Microbiol.
44: 3600-3607
[Abstract] [Full Text] -
Gordillo, R. M., Gutierrez, J., Casal, M.
(2005). Evaluation of the COBAS TaqMan 48 Real-Time PCR System for Quantitation of Hepatitis B Virus DNA. J. Clin. Microbiol.
43: 3504-3507
[Abstract] [Full Text] -
Marin, I. J., Poljak, M., Seme, K., Meglic-Volkar, J., Maticic, M., Lesnicar, G., Brinovec, V.
(2001). Comparative Evaluation of Semiautomated COBAS AMPLICOR Hepatitis B Virus (HBV) MONITOR Test and Manual Microwell Plate-Based AMPLICOR HBV MONITOR Test. J. Clin. Microbiol.
39: 758-761
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»